Sequential Phase II Study of the Anti-Idiotype Monoclonal Antibody Vaccine CeaVac and TriAb in Patients With Minimal Metastatic Colorectal Cancer
Sequential Phase II Study of the Anti-Idiotype Monoclonal Antibody Vaccine CeaVac and TriAb in Patients With Minimal Metastatic Colorectal Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.
PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have colorectal cancer that has spread to the liver.
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter study.
Beginning 6-12 weeks after curative hepatic resection, patients receive monoclonal antibody 3H1 anti-idiotype vaccine and monoclonal antibody 11D10 anti-idiotype vaccine intracutaneously at separate sites on days 1, 15, 29, and 45, then subcutaneously monthly for 4 months.
PROJECTED ACCRUAL: A total of 63 patients will be accrued for this study within 9 months.
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Gastrointestinal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
Los Angeles, California 90048, United States
Washington D.C., District of Columbia 20007, United States
Washington D.C., District of Columbia 20422, United States
Hollywood, Florida 33021, United States
Fort Wayne, Indiana 46885-5099, United States
Baltimore, Maryland 21201, United States
Boston, Massachusetts 02115, United States
Worcester, Massachusetts 01655, United States
Saint Joseph, Michigan 49085, United States
Columbia, Missouri 65203, United States
Omaha, Nebraska 68198-7680, United States
Lebanon, New Hampshire 03756-0002, United States
East Syracuse, New York 13057, United States
Syracuse, New York 13210, United States
Chapel Hill, North Carolina 27599-7295, United States
Wilmington, North Carolina 28402-9025, United States
Winston-Salem, North Carolina 27157-1082, United States
Roanoke, Virginia 24014, United States